Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical ...

Fintel reports that on October 31, 2024, Jones Trading initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Buy ...

周三，Jones Trading 开始对 ORIC Pharmaceuticals (NASDAQ: ORIC) 进行覆盖，给予买入评级，目标价为17.00美元。该公司的分析突出了 ORIC 专注于开发针对非小细胞肺癌（NSCLC）和转移性前列腺癌的靶向治疗药物，并指出公司经验丰富的管理团队此前在 Ignyta 公司成功开发了 entrectinib。

Fintel reports that on October 31, 2024, Wells Fargo initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...

Live webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the ...

Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2024 (the “Grant Date”), ...

Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have earned an average rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports.

Fintel reports that on October 31, 2024, Jones Trading initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Buy recommendation. As of October 22, 2024, the average one-year price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...